BLENOXANE (nda050443)- (EQ 15 UNITS BASE/VIAL,EQ 30 UNITS BASE/VIAL)
BLEOMYCIN SULFATE
BRISTOL MYERS SQUIBB
EQ 15 UNITS BASE/VIAL,EQ 30 UNITS BASE/VIAL
No
No
Expired
Expired
None
None
None
No
BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents:
* Squamous Cell Carcinoma
- Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to BLENOXANE is poorer in patients with previously irradiated head and neck cancer.
* Lymphomas
- Hodgkin’s disease, non-Hodgkin’s lymphoma.
* Testicular Carcinoma
- Embryonal cell, choriocarcinoma, and teratocarcinoma.
* BLENOXANE has also been shown to be useful in the management of:
* Malignant Pleural Effusion
- BLENOXANE is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.
